Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia is using its proprietary oral antibody platform to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
View Top Employees from Avaxia Biologics, Incorporated| Website | http://www.avaxiabiologics.com |
| Revenue | $5 million |
| Funding | $24 million |
| Employees | 3 (3 on RocketReach) |
| Founded | 2005 |
| Phone | (781) 861-0062 |
| Technologies |
JavaScript,
HTML,
reCAPTCHA
+8 more
(view full list)
|
| Category | Biotechnology, Drug Delivery, Pharmaceuticals, Science and Engineering, Healthcare, Medical Device, Health Care, Therapeutics |
| Web Rank | 38 Million |
| Competitors | Alzheon, Inc. | Preserving Future Memories, Axial Therapeutics, Inc., Compass Therapeutics Inc., ContraFect Corp, Excelimmune, Inc. |
| SIC | 873, 87 |
| NAICS | 54, 541714, 54171, 541, 5417 |
Looking for a particular Avaxia Biologics, Incorporated employee's phone or email?
Avaxia Biologics, Incorporated Questions
The Avaxia Biologics, Incorporated annual revenue was $5 million in 2023.
3 people are employed at Avaxia Biologics, Incorporated.
Avaxia Biologics, Incorporated is based in Lexington, Massachusetts.
The NAICS codes for Avaxia Biologics, Incorporated are [54, 541714, 54171, 541, 5417].
The SIC codes for Avaxia Biologics, Incorporated are [873, 87].
Top Avaxia Biologics, Incorporated Employees
Related Companies
